Malignant hematologic and solid tumor cells

Malignant hematologic and solid tumor cells refer to a diverse group of cancerous cells originating from either the blood, bone marrow, and lymph nodes or from solid organs and tissues [National Cancer Institute, 2023]. These cells are characterized by fundamental hallmarks of cancer, including sustained proliferative signaling, evasion of growth suppressors, and resistance to cell death [Hanahan & Weinberg, Cell, 2011]. While hematologic malignancies like leukemia and lymphoma often circulate or reside in the marrow, solid tumors such as carcinomas and sarcomas form discrete masses that can invade local tissues and metastasize [American Cancer Society, 2024]. In the context of drug development, these cells are the primary subjects of therapeutic intervention, yet they do not represent a single molecular target. Instead, they express a multitude of specific receptors, enzymes, and genetic mutations—such as BCR-ABL in chronic myeloid leukemia or HER2 in breast cancer—that serve as the actual targets for precision medicine [NIH, 2022]. Consequently, pharmacological strategies range from broad-spectrum cytotoxic agents to highly specific monoclonal antibodies and small molecule inhibitors designed to disrupt the unique biological pathways driving these malignant populations [Nature Reviews Drug Discovery, 2021].

Other names

Cancer cellsMalignant neoplasmsHematological and solid tumorsTumor cellsMalignant cells

Drugs targeting these cells act through diverse mechanisms including DNA damage, inhibition of signal transduction pathways, immune checkpoint blockade, and induction of apoptosis.